Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240988 | 0.78 | EPHX2 (0.37) | EPHX2HRH3L3MBTL1HSD11B1CNR1 | |
| SCHEMBL242613 | 0.76 | EPHX2 (0.48) | EPHX2HRH3L3MBTL1HSD11B1 | |
| SCHEMBL242960 | 0.72 | EPHX2 (0.49) | EPHX2HRH3L3MBTL1HSD11B1 | |
| SCHEMBL238884 | 0.72 | EPHX2 (0.47) | EPHX2HRH3L3MBTL1CNR1CNR2 | |
| SCHEMBL239046 | 0.72 | HSD11B1 (0.40) | EPHX2HRH3L3MBTL1HSD11B1KDM4E | |
| SCHEMBL241023 | 0.71 | EPHX2 (0.46) | EPHX2HRH3L3MBTL1HSD11B1 | |
| SCHEMBL240112 | 0.71 | CYP3A4 (0.41) | EPHX2HRH3L3MBTL1HSD11B1 | |
| SCHEMBL241230 | 0.70 | EPHX2 (0.52) | EPHX2HRH3L3MBTL1HSD11B1 | |
| SCHEMBL241231 | 0.70 | EPHX2 (0.52) | EPHX2HRH3L3MBTL1HSD11B1 | |
| SCHEMBL242362 | 0.70 | EPHX2 (0.45) | EPHX2HRH3L3MBTL1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | claimed |
| US-8053447-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | claimed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | claimed |
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
| US-8053447-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD11B2 | EPHX2 1354/4885HRH3 1997/4885L3MBTL1 4101/4885 |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HSD11B1, HSD3B1, HSD17B1 | EPHX2 1369/4885HRH3 2308/4885L3MBTL1 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.